KNE.V - Kane Biotech Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.1400
0.0000 (0.00%)
At close: 10:58AM EDT
Stock chart is not supported by your current browser
Previous Close0.1400
Open0.1425
Bid0.1350 x 0
Ask0.1400 x 0
Day's Range0.1400 - 0.1425
52 Week Range0.0800 - 0.2600
Volume15,500
Avg. Volume110,893
Market Cap15.206M
Beta (5Y Monthly)0.49
PE Ratio (TTM)N/A
EPS (TTM)-0.0120
Earnings DateApr. 01, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Kane Biotech Announces Fourth Quarter and Full Year 2019 Financial Results

    WINNIPEG, Manitoba, April 02, 2020 -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and.

  • GlobeNewswire

    Kane Biotech Reschedules Release of Fourth Quarter and Full Year 2019 Financial Results and Associated Conference Call to April 2, 2020

    WINNIPEG, Manitoba, March 25, 2020 -- Further to its press release of March 20, 2020, Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company) announced that, in response.

  • GlobeNewswire

    Kane Biotech to Release Fourth Quarter and Full Year 2019 Financial Results on March 26 – Conference Call to Follow

    WINNIPEG, Manitoba, March 20, 2020 -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and.

  • GlobeNewswire

    Kane Biotech Announces Grant of Stock Options

    WINNIPEG, Manitoba, March 02, 2020 -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today announces that it granted an aggregate of 3,650,000 stock options.

  • GlobeNewswire

    Kane Biotech Launches silkstem™ Anti-Itch Shampoo at the Global Pet Expo

    Kane Biotech Inc. (KNE.V) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced the launch of its silkstemTM anti-itch shampoo (www.silkstempets.com) at the Global Pet Expo taking place on February 26-28, 2020 at the Orange County Convention Center in Orlando, Florida. “The launch of silkstemTM is an important milestone for Kane Biotech as it’s our second animal health product line and we believe it will generate the same amount of interest as our bluestem™ line of oral care products,” said Marc Edwards, CEO of Kane Biotech. Kane Biotech will be located in booth 4151 and will be accepting orders for its silkstemTM as well as its bluestemTM oral care line of products from U.S. retailers.

  • GlobeNewswire

    Kane Biotech Signs First U.S. Distribution Agreement with King Wholesale Inc.

    Kane Biotech Inc. (KNE.V) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that it has signed an agreement with King Wholesale Inc. (“King”), a California-based distributor of wholesale pet supplies. Under the terms of the agreement, King will distribute Kane Biotech’s bluestem™ oral care and silkstem™ anti-itch shampoo products to its customers across the U.S.

  • GlobeNewswire

    Kane Biotech Announces Closing of Second and Final Tranche of Private Placement

    Kane Biotech Inc. (KNE.V) (the “Company” or “Kane Biotech”) is pleased to announce that it has closed the second tranche (the “Second Tranche”) of its non-brokered private placement offering (the “Offering”) previously announced on December 4, 2019, and has issued 7,081,862 units of the Company ("Units") at a price of $0.14 per Unit to raise gross proceeds of $991,460.68. Each Unit consists of one common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant (a "Warrant"), with each whole Warrant entitling the holder thereof to purchase one additional Common Share at an exercise price of $0.18 per Common Share until February 24, 2022.

  • GlobeNewswire

    Kane Biotech Welcomes Renowned Canadian Veterinarian, Dr. Jean Gauvin, as Chief Veterinary Officer

    Kane Biotech Inc. (KNE.V) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that it has appointed Jean Gauvin, DVM, as its Chief Veterinary Officer (“CVO”), effective immediately. In the newly-created position of CVO, Dr. Gauvin will serve as a liaison between Kane Biotech and industry, guide the Kane Biotech R&D team’s Animal Health research and product development, and be the media voice of Kane Biotech’s Animal Health business unit.

  • GlobeNewswire

    Kane Biotech Engages Independent Trading Group, Inc. for Market-Making Services

    Kane Biotech Inc. (KNE.V) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, is pleased to announce that, subject to regulatory approval, it has retained Independent Trading Group, Inc. (“ITG”) to provide market-making services to the Company (the ”Engagement”). ITG will trade shares of Kane Biotech on the TSX Venture Exchange (“TSX-V”) in compliance with the policies and guidelines of the TSX-V and other applicable legislation with the objective of maintaining a reasonable market and improving the liquidity of the common shares of the Company.

  • GlobeNewswire

    Kane Biotech Provides Update on Previously Announced Private Placement

    Kane Biotech Inc. (KNE.V) (the “Company” or “Kane Biotech”), in accordance with the policies of the TSX Venture Exchange (“TSX-V”), wishes to provide an update on the status of the non-brokered private placement of the Company’s units (“Units” and each a “Unit”) at $0.14 per Unit for gross proceeds of up to $3,500,000 (the “Offering”), initially announced by the Company on December 4, 2019. Each Unit offered under the Offering consists of a common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant (each, a “Warrant”).

  • GlobeNewswire

    Kane Biotech Announces Closing of First Tranche of Private Placement

    Kane Biotech Inc. (KNE.V) (the “Company” or “Kane Biotech”) is pleased to announce that it has closed the first tranche (the “First Tranche”) of its non-brokered private placement offering (the “Offering”) announced previously on December 4, 2019, and has issued 17,918,137 units of the Company ("Units") at a price of $0.14 per Unit to raise gross proceeds of $2,508,539.18. Each Unit consists of one common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant (a "Warrant"), with each whole Warrant entitling the holder thereof to purchase one additional Common Share at an exercise price of $0.18 per Common Share until December 19, 2021.

  • GlobeNewswire

    Kane Biotech Announces Fulfilment of First Major Animal Oral Care Product Order from China

    WINNIPEG, Manitoba, Dec. 17, 2019 -- Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and.

  • GlobeNewswire

    Kane Biotech Launches Consumer Product Test for an Innovative Shampoo Containing its Patented Anti-Biofilm Technology

    Kane Biotech Inc. (KNE.V) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that it has launched a consumer product test to evaluate the efficacy of its new shampoo on dermatitis and dandruff. Recent research has indicated that the persistence of microbial biofilm may be linked with aggravating the symptoms associated with atopic dermatitis, seborrheic dermatitis (also known as eczema) and dandruff. Kane Biotech’s shampoo consists of coactiv+TM, a patented anti-biofilm formulation, and contains ingredients approved as safe for human use.

  • GlobeNewswire

    Kane Biotech Announces Private Placement Offering

    Kane Biotech Inc. (KNE.V) (the “Company” or “Kane Biotech”) today announced its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 25,000,000 units (“Units”) at a price of $0.14 per Unit for gross proceeds of up to $3,500,000. Each Unit shall be comprised of one common share and one-half of one common share purchase warrant (a “Warrant”). Each full Warrant shall entitle the holder thereof to purchase one additional common share of the Company for a period of two years, at an exercise price of $0.18 per share.

  • GlobeNewswire

    Kane Biotech Announces Conditional Research Award of Up To $3.4 Million

    Kane Biotech Inc. (KNE.V) (the “Company” or “Kane Biotech”) today announced that it has been selected to receive a potential award of up to approximately $3.4 million from an unnamed government agency related to the continuing clinical development of the Company’s DispersinB® to treat biofilm mediated antimicrobial resistance in non-healing chronic wounds.

  • GlobeNewswire

    Kane Biotech to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

    Kane Biotech Inc. (KNE.V) (the “Company” or “Kane Biotech”) announced today that management will present an update on the Company’s business at the first annual BioTuesdays Pre-JPM Virtual Conference on Tuesday, December 10, 2019 at 2:00 p.m. Eastern Time. The presentation will be broadcast live and archived on the Company's website at www.kanebiotech.com under "News/Events" in the Investors section. Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

  • GlobeNewswire

    Kane Biotech Engages Kilmer Lucas for Cross-Border Investor Relations

    Kane Biotech Inc. (KNE.V) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that that it has engaged Kilmer Lucas Inc. (“Kilmer Lucas”) to provide the Company with select U.S. and Canadian investor relations (“IR”) and strategic advisory services. Employing an ‘outsourced in-house’ partnership model, Kilmer Lucas designs and executes customized IR programs for healthcare companies. “Having undergone a company-wide transformation during the past year, we evaluated a number of IR firms that could support our continued growth and help us communicate our progress to a broader investor audience, and upon the recommendation of a trusted advisor, we selected Kilmer Lucas,” stated Marc Edwards, CEO of Kane Biotech.

  • GlobeNewswire

    Kane Biotech Announces Third Quarter 2019 Financial Results

    WINNIPEG, Manitoba, Nov. 14, 2019 -- Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and.

  • GlobeNewswire

    Kane Biotech Announces Date of Q3 Earnings Release

    WINNIPEG, Manitoba, Nov. 06, 2019 -- Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and.

  • GlobeNewswire

    Kane Biotech Retains GR Consulting to Identify Potential Partnerships for its Proprietary DispersinB® Wound Care Hydrogel

    Kane Biotech Inc. (KNE.V), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, is pleased to announce that they have retained GR Consulting to develop and implement the out-licensing strategy for their DispersinB® wound care Hydrogel for both the United States and European markets. “Gary and Edwin have years of experience and an exhaustive network in the wound care space that will allow Kane to not only accelerate the licensing of our technology, but also maximize the value of a future licensing agreement”, said Marc Edwards, Kane Biotech CEO.

  • GlobeNewswire

    Kane Biotech and Dechra Veterinary Products Expand Exclusive License and Distribution Agreement to Include South America

    Kane Biotech Inc. (KNE.V), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms and Dechra Veterinary Products LLC (“Dechra”) a wholly-owned subsidiary of Dechra Pharmaceuticals PLC (LSE:DPH) today announced the expansion of their 10-year Exclusive License and Distribution Agreement to include South America. Kane Biotech will receive an upfront payment upon the first commercial sale of Vetradent in Brazil, as well as an ongoing royalty on net Vetradent sales in South America, Terms of the Agreement are confidential between the parties and further financial details are not disclosed.

  • GlobeNewswire

    Kane Biotech Receives Funding for Research and Development

    Kane Biotech Inc. (KNE.V), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, is pleased to announce that they have been awarded a non-repayable contribution of up to CAD $340,680 from the National Research Council of Canada Industrial Research Assistance program (NRC IRAP). Kane intends to use this funding to support research and development in order to enhance its quality assurance, quality control, and supply chain capabilities to support its rapidly growing animal health sales and commercialization efforts.

  • Here's Why Kane Biotech (CVE:KNE) Can Afford Some Debt
    Simply Wall St.

    Here's Why Kane Biotech (CVE:KNE) Can Afford Some Debt

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • GlobeNewswire

    Kane Biotech Releases Inaugural Business Update Video

    Kane Biotech Inc. (KNE.V), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today hosted their first-ever business update. “I joined Kane Biotech exactly one year ago today, and I am proud to say that we’ve made notable progress on all of the initiatives that were laid out when I began.” stated Marc Edwards, Chief Executive Officer of Kane Biotech.

  • GlobeNewswire

    Kane Biotech Announces Second Quarter 2019 Financial Results

    WINNIPEG, Manitoba, Aug. 21, 2019 -- Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and.